The latest price target for Rigel Pharmaceuticals (NASDAQ:RIGL) was reported by HC Wainwright & Co. on January 22, 2025. The analyst firm set a price target for $57.00 expecting RIGL to rise to within 12 months (a possible 182.88% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Rigel Pharmaceuticals (NASDAQ:RIGL) was provided by HC Wainwright & Co., and Rigel Pharmaceuticals reiterated their buy rating.

The last upgrade for Rigel Pharmaceuticals Inc happened on December 2, 2022 when Citigroup raised their price target to N/A. Citigroup previously had a neutral for Rigel Pharmaceuticals Inc.

The last downgrade for Rigel Pharmaceuticals Inc happened on June 9, 2022 when Citigroup changed their price target from $7 to $0.8 for Rigel Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on January 22, 2025 so you should expect the next rating to be made available sometime around January 22, 2026.

While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a reiterated with a price target of $57.00 to $57.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $20.15, which is out of the analyst’s predicted range.